Drug Profile
Research programme: Charcot-Marie-Tooth disease therapeutics - Charcot-Marie-Tooth Association/Sanofi
Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Charcot-Marie-Tooth Association; Genzyme Corporation
- Developer Charcot-Marie-Tooth Association; Sanofi
- Class Small molecules
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Charcot-Marie-Tooth disease
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for research development in Charcot-Marie-Tooth-disease in USA
- 22 Sep 2014 Early research in Charcot-Marie-Tooth disease in USA (unspecified route)